Navigation Links
A new class of anti-inflammatory drugs
Date:12/10/2008

This release is available in German.

In the treatment of pain, inflammation and fever, non-steroid anti-rheumatic drugs (NSAR) such as acetylsalicylic acid - more commonly known as Aspirin - or Ibuprofen have always been popular choices. However, had they been tested using today's stringent criteria, many of these drugs would not have passed the clinical trial stage, due to the potential risks and side effects they entail. This suggests the need for more innovative thinking in this area of drug therapy. One such new approach has been developed in Manfred Schubert-Zsilavecz's laboratory at the Goethe University, using chemical substances belonging to the dual mPGES-1/5-LO-Inhibitors. Oliver Werz's group at Tbingen has characterized the substances at the molecular/pharmacological level. Their research results now form the basis of a joint patent application, and a publication in the renowned "Journal of Medicinal Chemistry" (Koeberle et al, J Med Chem (2008), Nov 19. [Epub ahead of print]).

Aspirin and the related NSAR drugs act on the arachidonic acid biosynthesis cascade, which plays a central role in the onset of pain and inflammation. They thus prevent the synthesis of specific prostaglandins, which are essential for vital bodily functions. When the drugs are taken over a long period of time, the unselective inhibition of this essential pathway may result in unwanted side effects on the gastrointestinal tract and the cardiovascular system. As Schubert-Zsilavecz explains: "By comparison, our class of drugs/substances acts on a later stage in the arachidonate cascade, and is more selective. We therefore can expect it to have considerably fewer side effects."

A further advantage of this new class of drugs is that they not only specifically target the biosynthesis of prostaglandin, but also of leukotrienes, which are metabolites in the second important branch of the arachidonate cascade and play a central role in allergic and inflammatory reactions. This double attack promises more effective results for these new substances.

Gerd Geisslinger, Speaker of the LiFF-Initiative and President of the Center for Drug Research, Development and Safety (ZAFES) explains: "This is a most important success for our newly established Lipid Signalling Research Centre, which was established only a short time ago under the LOEWE initiative, funding research in the German state Hesse."


'/>"/>

Contact: Manfred Schubert-Zsilavecz
Schubert-Zsilavecz@pharmchem.uni-frankfurt.de
49-069-798-29339
Goethe University Frankfurt
Source:Eurekalert  

Related medicine news :

1. Popular class of diabetes drugs doubles risk of fractures in women
2. Triple-S Management Corporation Announces Conversion of Class A Shares and Commencement of Class B Stock Repurchase Program
3. Frost & Sullivan Recognises Best-in-Class Innovators
4. On Staying Alives 10th Anniversary, Gym Class Heroes Singer Travis McCoy Named 2009 Foundation Ambassador
5. Scientists at CSHL uncover new RNA processing mechanism and a new class of small RNAs
6. Foundation Radiology Group Adds World Class Cardiovascular Imaging Expert, Dr. Sanj Katyal, to Staff
7. Magistrate Judge Recommends Denial of Class Certification in Funeral Industry Antitrust Litigation
8. Alex Rodriguez, Ryan Howard and Terry Francona to Headline David Ortiz Celebrity Golf Classic
9. Avandias Heart Risk Higher Than Others in Its Class
10. Law Offices of Howard G. Smith Announces Class Action Lawsuit on Behalf of Investors of PharmaNet Development Group, Inc.
11. OmniVision Unveils 1.8 mm, Low Power Medical Sensor With Best-in-Class Low Light Performance
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
A new class of anti-inflammatory drugs
(Date:2/22/2017)... Wis (PRWEB) , ... February 22, 2017 , ... ... a category by itself - the Vector™ Series Multi-Cook Oven offers up to ... oven chamber, featuring exclusive Structured Air Technology™ for unmatched evenness in cooking. Alto-Shaam ...
(Date:2/21/2017)... , ... February 21, 2017 , ... ... Nation Regional Medical Clinic in Durant, Oklahoma, on Feb. 21. , The celebration ... tours for community members, clinic employees, the construction team and tribal leadership. ...
(Date:2/21/2017)... ... ... As recently as 2015, rhinoplasty was one of the Top 5 cosmetic ... patients want to make a change in the appearance of their nose while others ... team at usrhinoplasty.org is expanding its article database to better inform its ...
(Date:2/21/2017)... ... February 21, 2017 , ... American Veterinarian™, the premier ... be launching its first bi-monthly issue of 2017 in February. The inaugural issue ... and One Health. , In making the announcement, American Veterinarian™ Publisher Chris ...
(Date:2/21/2017)... California (PRWEB) , ... February 21, 2017 , ... ... world with over 50,000 participants. The connected care demonstration spanned multiple health ... the National Coordinator, roughly 30% of providers have no Health Information Exchange outside ...
Breaking Medicine News(10 mins):
(Date:2/22/2017)... , Colombie-Britannique, February 22, 2017 Des scanners ... la vente en Europe , au Moyen-Orient et en ... Clarius Mobile Health ... Vancouver , au Canada , a ... commerciale des Scanners Échographiques Sans fil Clarius C3 et L7, destinés à ...
(Date:2/22/2017)...  Soligenix, Inc. (Nasdaq: SNGX ) ... focused on developing and commercializing products to treat ... need, announced today that its proprietary formulation of ... for the treatment of psoriasis. The issued patent, ... skin conditions, complements the method of treatment claims ...
(Date:2/21/2017)... 2017 The global infusion pumps market is ... 2016 to 2021, to reach USD 10.84 billion by ... of chronic diseases along with increasing geriatric population, increasing ... steady increase in surgical procedural volumes, and rising applications ... the key factors driving the growth of this market. ...
Breaking Medicine Technology: